> top > docs > PMC:7228307 > spans > 53179-54143 > annotations

PMC:7228307 / 53179-54143 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id tao:has_standard_notation
1088 3-8 Gene denotes FcγRI Gene:2214
1089 13-20 Gene denotes FcγRIIb Gene:2213
1090 276-280 Gene denotes FcγR Gene:2213
1091 75-79 Gene denotes FcγR Gene:2213
1092 578-582 Gene denotes FcγR Gene:2213
1093 400-410 Chemical denotes disulfides MESH:D004220
1094 36-62 Disease denotes PD‐1 antibody tislelizumab MESH:D010300
1095 191-196 Mutation denotes E233P p.E233P
1096 198-203 Mutation denotes F234V rs755807976
1097 205-210 Mutation denotes L235A p.L235A
1098 238-243 Mutation denotes D265A p.D265A
1099 341-346 Mutation denotes S228P rs1469294455
1100 359-364 Mutation denotes L309V p.L309V
1101 369-374 Mutation denotes R409K p.R409K
1104 802-806 Gene denotes FcγR Gene:2213
1105 671-675 Gene denotes FcγR Gene:2213
1107 894-901 Gene denotes FcγRIIb Gene:2213
1110 957-964 Gene denotes FcγRIIb Gene:2213

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T409 41-49 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T410 471-473 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T411 750-759 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T896 3-5 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T897 13-15 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T898 63-66 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T899 75-77 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T900 128-132 http://purl.obolibrary.org/obo/CLO_0007179 denotes L235
T901 188-189 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T902 268-269 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T903 276-278 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T904 305-308 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T905 556-557 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T906 578-580 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T907 606-616 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T908 626-628 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T909 671-673 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T910 770-771 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T911 802-804 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T912 894-896 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T913 940-942 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T914 957-959 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T28 6-8 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T85014 36-38 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T2607 400-410 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343
T70545 676-684 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T34 863-871 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T228 685-694 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T229 872-881 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T59 400-410 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes pubann:has_HGVS_notation
1088 3-8 Gene denotes FcγRI Gene:2214
1089 13-20 Gene denotes FcγRIIb Gene:2213
1090 276-280 Gene denotes FcγR Gene:2213
1091 75-79 Gene denotes FcγR Gene:2213
1092 578-582 Gene denotes FcγR Gene:2213
1093 400-410 Chemical denotes disulfides MESH:D004220
1094 36-62 Disease denotes PD‐1 antibody tislelizumab MESH:D010300
1095 191-196 Mutation denotes E233P p.E233P
1096 198-203 Mutation denotes F234V rs755807976
1097 205-210 Mutation denotes L235A p.L235A
1098 238-243 Mutation denotes D265A p.D265A
1099 341-346 Mutation denotes S228P rs1469294455
1100 359-364 Mutation denotes L309V p.L309V
1101 369-374 Mutation denotes R409K p.R409K
1104 802-806 Gene denotes FcγR Gene:2213
1105 671-675 Gene denotes FcγR Gene:2213
1110 957-964 Gene denotes FcγRIIb Gene:2213

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T303 22-296 Sentence denotes The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2.
T304 297-514 Sentence denotes It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4.
T305 515-619 Sentence denotes Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17
T306 620-882 Sentence denotes Thus, Fc engineering is an effective way to remove FcγR effector functions and may be preferable to using unmodified IgG2 or IgG4 backbones that have a more restricted repertoire of FcγR interactions but which are still able to induce certain effector functions.
T307 884-914 Sentence denotes Improving FcγRIIb interactions

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T715 36-40 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T408 41-49 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T409 471-473 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T410 750-759 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478

LitCovid-sample-PD-GO-BP-0

Id Subject Object Predicate Lexical cue
T122 474-482 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 595-616 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation

LitCovid-sample-GO-BP

Id Subject Object Predicate Lexical cue
T122 474-482 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 595-616 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T122 474-482 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 595-616 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T303 22-296 Sentence denotes The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2.
T304 297-514 Sentence denotes It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4.
T305 515-619 Sentence denotes Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17
T306 620-882 Sentence denotes Thus, Fc engineering is an effective way to remove FcγR effector functions and may be preferable to using unmodified IgG2 or IgG4 backbones that have a more restricted repertoire of FcγR interactions but which are still able to induce certain effector functions.
T307 884-914 Sentence denotes Improving FcγRIIb interactions